Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.

Check Now!
SALE Triple Negative Breast Cancer Market Assessment
Triple Negative Breast Cancer Market Assessment
Triple Negative Breast Cancer (TNBC) - Market Insight, Epidemiology And Market Forecast - 2032
  • Published Date : Sep 2023

  • Pages : 200

  • Delivery Time : 24 Hours

  • Region : United States, EU5, Japan

Triple Negative Breast Cancer Market

Key Highlights

  • Breast cancer is a genetically and clinically heterogeneous disease with multiple subtypes. The classification of these subtypes has evolved over the years. The most common and widely accepted classification of breast cancer is from an immunohistochemical perspective, based on the expression of the following hormone receptors: estrogen (ER), progesterone (PR), and human epidermal growth factor (HER2)
  • TNBC’s distinct immune microenvironment, which includes high levels of vascular endothelial growth factors, tumor-infiltrating lymphocytes (TILs), tumor-associated macrophages (TAMs), and other molecules that promote tumor cell growth and migration, plays a dual role in the occurrence, growth, and metastasis of the disease.
  • TNBC risk factors have been classified as either non-modifiable or modifiable. Age, sex, genetic mutations, genetic history, breast tissue density, and others are non-modifiable risk variables. Modifiable risk factors include medicines, BMI, inadequate vitamin supplements, chemical and drug exposure, and so on.
  • TNBC can manifest as a higher-grade malignancy at first and have a more aggressive clinical course than other kinds of breast cancer. In addition, the rate of distant metastatic disease is greater, and the mean time to distant metastatic disease is shorter. Because of the absence of endocrine receptor expression, interventions are restricted. TNBC has a worse prognosis and greater mortality with residual illness than non-TNBC because of its aggressive course, high rates of recurrence, and limited therapy alternatives.
  • Approximately half of the breast cancers, historically categorized as human epidermal growth factor receptor 2 (HER2)-negative, have low expression of HER2, defined as an immunohistochemical (IHC) score of 1+ or 2+ with negative in situ hybridization. The current clinical definition of HER2-low BC used in clinical practice and ongoing clinical trials relies on the standard IHC and ISH approach; thus, tumors with a low level of HER2 expression (defined as a HER2 IHC score of 1+ or 2+) and no detectable ERBB2 amplification fall into this category.
  • Regarding the epidemiology of TNBC, it was found that the United States accounted for ~42% of the total cases of TNBC in the 7MM.
  • The market size captured by the United States was found to be the largest among the 7MM countries. It was found that the United States accounted for ~61% of the total market size captured by the 7MM region.
  • The term “triple negative breast cancer diagnosis” is somewhat misnomer. Rather than being an official medical diagnosis, TNBC refers to the cellular makeup of certain breast cancers, which can influence a patient’s prognosis. The pathology for these cancers usually shows that the cancer cells tested negatively for three specific hormone receptors: estrogen, progesterone, and HER-2/neu.
  • In contrast to hormone receptor (ER/PR)-positive and HER2-positive breast cancers, there are few FDA-approved targeted therapies for triple-negative breast cancer. Historically, chemotherapy has been the main systemic treatment, especially for patients with metastatic disease; although TNBC tends to respond well to chemo initially, recurrences are frequent.
  • The recent approval of various immune checkpoint inhibitors (like pembrolizumab) and targeted therapies (like olaparib and talazoparib) has led to a dynamic shift in the treatment landscape, with their increased usage across various lines of therapy, leading to significant improvement in treatment outcomes and patient prognosis.
  • The emerging pipeline for TNBC patients consists of early-stage and late-stage drugs in various lines of therapy. As per DelveInsight’s estimates, the potential drugs that can significantly change in the market during the forecast period include COSELA, Capivasertib, Datopotamab Deruxtecan (Dato-DXd), ZEN003694 and TAVO (tavokinogene telseplasmid) being administered in various combinations. These drugs are in different stages of clinical development.

Report Summary

  • The report covers a segment of key events describing the latest developments from a treatment point of view, including designations, collaboration, and agreements, etc., as well as a descriptive overview of Triple Negative Breast Cancer (TNBC), explaining the definition of Triple Negative Breast Cancer (TNBC), types and risk factors involved in Triple Negative Breast Cancer (TNBC), pathophysiology, and the treatment of Triple Negative Breast Cancer (TNBC).
  • The report offers extensive knowledge regarding the epidemiology segments and predictions, presenting a deep understanding of the potential future growth in diagnosis rates, disease progression, and treatment guidelines. It provides comprehensive insights into these aspects, enabling a thorough assessment of the subject matter.
  • Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage (Phase III and Phase II) and prominent therapies that would impact the current treatment landscape and result in an overall market shift has been provided in the report.
  • The report also encompasses a comprehensive analysis of the Triple Negative Breast Cancer (TNBC) market, thoroughly examining its historical and projected market size (2019-2032). It also includes the market share of therapies, along with detailed assumptions and the underlying rationale for methodology. The report also includes the drug outreach coverage in the 7MM region.
  • The report includes qualitative insights that provide an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, including experts from various hospitals and prominent universities, patient journey, and treatment preferences that help shape and drive the 7MM Triple Negative Breast Cancer (TNBC) market.

The table given below further depicts the key segments provided in the report:

Study Period

2019–2032

Forecast Period

2023–2032

Geographies Covered

The US, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan

Epidemiology

Segmented by:

  • Region
  • Subtype-specific classification
  • Gene mutation-specific classification
  • Stage-specific classification
  • Age-specific classification

Market

Segmented by:

  • Region
  • Therapies

Market Analysis

  • KOL Views
  • SWOT Analysis
  • Unmet Needs

Market

  • Various key players are currently leading the treatment landscape of TNBC, such as G1 Therapeutics, AstraZeneca, Zenith Epigenetics, etc. The details of the country and therapywise market size have been provided below.
  • In 2022, the United States accounted for the largest market size among the 7MM countries, making ~61% of the total market size of the 7MM.
  • Among the 7MM countries, Spain had the least market size in 2022, accounting for ~3% of the market size in the 7MM region.
  • In the EU4 region, Germany accounted for the largest market size, making up ~29% of the total market size of the EU4 region.
  • The market size has also been segregated linewise. In 2022, among the therapies being administered to first-line patients, KEYTRUDA (pembrolizumab) + paclitaxel/nab-paclitaxel/gemcitabine + carboplatin combination garnered the largest market share in the 7MM region.

triple-negative-breast-cancer-tnbc-epidemiology

Triple Negative Breast Cancer (TNBC) Drug Chapters

The section dedicated to drugs in the Triple Negative Breast Cancer (TNBC) report provides an in-depth evaluation of both the marketed drugs and late-stage pipeline drugs (Phase III and Phase II) related to TNBC. Among the FDA-approved treatments are LYNPARZA (olaparib), TALZENNA (talazoparib), KEYTRUDA (pembrolizumab), and others. There are several emerging therapies, and detailed coverage of the same has been provided in the report.

The drug chapters section provides valuable information on various aspects related to clinical trials of TNBC, including specific details, such as the pharmacological mechanisms of the drugs involved, agreements and partnerships, approval status, patent information, and a comprehensive analysis of the pros and cons associated with each drug. Furthermore, it presents the most recent news updates and press releases related to drugs targeting TNBC.

Marketed Therapies

LYNPARZA (olaparib)

LYNPARZA (olaparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor. LYNPARZA is indicated for the treatment of adult patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with prior endocrine therapy or be considered inappropriate for endocrine therapy.

TALZENNA (talazoparib)

Talazoparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1 and PARP2, which play a role in DNA repair. TALZENNA is indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA.

Therapy Name

Company

Patient Segment

The US Approval Year

LYNPARZA

AstraZeneca

Adult patients with deleterious or suspected deleterious germline BRCA mutation who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting

2021

TALZENNA

Pfizer

Patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer

2018

Triple Negative Breast Cancer (TNBC) Market Outlook

Unlike other forms of breast cancer, TNBC does not respond with hormonal or HER2-targeted treatment. Hence, for a long time, systemic chemotherapy has remained the mainstay treatment for metastatic TNBC. Even for resectable/non-metastatic disease, chemotherapy and surgery in neoadjuvant or adjuvant therapy have been widely used.

But the recent approval of various immune checkpoint inhibitors (like pembrolizumab) and targeted therapies (like olaparib and talazoparib) has led to a dynamic shift in the treatment landscape, with their increased usage across various lines of therapy, leading to significant improvement in treatment outcomes and patient prognosis.

In patients with localized TNBC, dose-dense doxorubicin-cyclophosphamide, and paclitaxel were the standard neoadjuvant chemotherapy backbone until 2021. With the approval of neoadjuvant pembrolizumab, chemotherapy with immunotherapy is the new standard of care for localized TNBC.

Before these recent developments, taxane-based chemotherapies have remained the standard of care for metastatic disease, specifically in first-line treatment. However, with their recent approvals, immune checkpoint inhibitors like pembrolizumab and atezolizumab have established their effectiveness when combined with taxane-based chemotherapies; however, their usage is limited to patients with high levels of PD-L1 expression. Due to their superior results, they remain the most preferred form of treatment in the first-line setting.

The TNBC market is witnessing significant growth and evolution due to increased awareness, technological advancements, therapeutic advancements, and integration into clinical trials. However, challenges related to cost, access, and market competition remain important considerations for TNBC, keeping the dynamic market scenario in mind.

Drug Class Insights

Treatment for triple-negative breast cancer (TNBC) is more difficult since there is no apparent therapeutic target, as there is for ER/PR-positive or HER2-positive breast cancer. TNBC is treated with surgery, chemotherapy, and radiation.

The second most preferred form of treatment are poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors LYNPARZA (olaparib) and TALZENNA (talazoparib); their usage is preferred in patients with germline BRCA1/2 mutations. Platinum-based chemotherapies are also used at times in the first-line treatment setting, but their usage is highly debated among physicians, as they tend to have very severe adverse effects and do not have that good of treatment outcome (PFS) either.

For patients with recurrent/refractory metastatic TNBC (mTNBC), the antibody–drug conjugate TRODELVY (sacituzumab govitecan-hziy) has emerged as an effective treatment option, in the second-line of the treatment. It targets Trop-2, which is present in most patients with triple-negative disease.

Triple Negative Breast Cancer (TNBC) Disease Understanding and Treatment

Triple Negative Breast Cancer (TNBC) Overview

Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of fundamentally different diseases with different histologic, genomic, and immunologic profiles, which are aggregated under this term because of their lack of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expressions. Massively parallel sequencing and other omics technologies have demonstrated the level of heterogeneity in TNBCs and shed light on the pathogenesis of this therapeutically challenging entity in breast cancer.

Triple Negative Breast Cancer (TNBC) diagnosis

The phrase “triple negative breast cancer (TNBC) diagnosis” is a bit misleading. TNBC refers to the cellular composition of some breast tumors, which might impact a patient’s prognosis rather than an official medical diagnosis. Pathology for these malignancies typically reveals that the cancer cells tested negative for three hormone receptors: estrogen, progesterone, and HER-2/neu. The first step in developing an effective treatment strategy is to confirm any breast cancer diagnosis. A triple negative test result means these hormones will not promote cancer development. Another problem is that standard breast cancer hormone treatment, such as tamoxifen or aromatase inhibitors, is unsuccessful in treating these tumors.

Further details related to country-based variations are provided in the report…

triple-negative-breast-cancer-tnbc-market

Triple Negative Breast Cancer (TNBC) Treatment

Triple-negative breast cancer (TNBC) represents a small but aggressive subtype of breast cancer with high mortality, partly because many cancers become metastatic. Relapse is common in TNBC, including for women with localized disease. TNBCs test negative for progesterone, estrogen receptors, and excess HER2 protein. For these reasons, this cancer type is not responsive to hormonal or HER2-targeted therapies.

In contrast to hormone receptor (ER/PR)-positive and HER2-positive breast cancers, there are few FDA-approved targeted therapies for triple-negative breast cancer. Historically, chemotherapy has been the main systemic treatment, especially for patients with metastatic disease; although TNBC tends to respond well to chemo initially, recurrences are frequent.

Patients have a worse prognosis with fewer treatment options than other breast cancer subtypes, and TNBC is more resistant to conventional treatment. Overall survival rates for TNBC patients with advanced or Stage IV disease is approximately 12 months compared to 36 months for those with ER-positive/PR-positive/HER2-negative disease.

But, of late, this pattern of treatment and survival is changing, as with an increased understanding of the disease’s pathophysiology, TNBC is classified into several distinct molecular subtypes based on gene expression profiles rather than being considered a single disease. Following these developments, accompanied by newer therapies being recently approved, there has been improvement in the prognosis of patients.

Further details related to treatment and management are provided in the report…

Triple Negative Breast Cancer (TNBC) Epidemiology

The Triple Negative Breast Cancer (TNBC) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Triple Negative Breast Cancer (TNBC), Subtype-specific Cases of Triple Negative Breast Cancer (TNBC), Gene Mutation-specific Cases of Triple Negative Breast Cancer (TNBC), Stage-specific Cases of Triple Negative Breast Cancer (TNBC), Age-specific Cases of Triple Negative Breast Cancer (TNBC) and Line wise Treated Cases of Triple Negative Breast Cancer (TNBC) in the 7MM covering the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2019 to 2032.

  • The total incident cases of TNBC in the United States comprised ~43,000 cases in 2022. These cases are expected to increase by 2032.
  • Among the EU4 countries, Germany accounted for the highest number of incident cases of TNBC, i.e., ~10,750 cases in 2022. Whereas Spain accounted for the least number of cases, i.e., ~5,200 cases in 2022.
  • In Japan, as per subtype-specific classification, the HER2-negative cases were found to be the highest in number, ~8,400 cases, in 2022.
  • As per gene mutation-specific cases, the BRCA1 cases were found to be the highest in number, i.e., ~730 cases in 2022, in the UK.

Segment

Region

Cases in 2022 (% out of total cases in the 7MM)

Total Incident Cases of TNBC

The US

~42%

EU4 and the UK

~43%

Japan

~15%

Report Metrics

Details

Study Period

2019 to 2032

Base Year

2021

Forecast Period

2022 to 2032

CAGR

Request Sample to Know

TNBC Cases

XXXX Cases in 2022

Key Companies

AstraZeneca, Gilead Science, Infinity Pharmaceuticals, HiberCell, Hoffmann-La Roche, Immunomedics, Merck, HiberCell, Infinity Pharmaceuticals, CytoDyn, and Many Others.

KOL Views

To stay abreast of the latest trends in the market, we conduct primary research by seeking the opinions of Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) who work in the relevant field. This helps us fill any gaps in data and validate our secondary research.

We have reached out to industry experts to gather insights on various aspects related to Triple Negative Breast Cancer (TNBC), including the evolving treatment landscape, patients’ reliance on conventional therapies, their acceptance of therapy switching, drug uptake, and challenges related to accessibility. The experts we contacted included medical/scientific writers, professors, and researchers from prestigious universities in the US, Europe, the UK, and Japan.

Our team of analysts at Delveinsight connected with more than 10 KOLs across the 7MM. We contacted institutions such as the National Cancer Center Hospital, University of Messina, Icahn School of Medicine, and Tufts Medical Center, among others. By obtaining the opinions of these experts, we gained a better understanding of the current and emerging treatment patterns in the Triple Negative Breast Cancer (TNBC) market, which will assist our clients in analyzing the overall epidemiology and market scenario.

Qualitative Analysis

We conduct qualitative and market intelligence analysis by employing the SWOT analysis approach. Within the SWOT analysis framework, we assess the strengths, weaknesses, opportunities, and threats pertaining to various aspects such as disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies. This analysis provides a comprehensive evaluation of the current situation and helps identify areas of advantage, areas for improvement, potential opportunities, and potential challenges in the specified domains.

Market Access and Reimbursement

Cancer treatments are funded in several countries through public reimbursement programs. This type of support promotes equitable access for people by removing direct fees from patients. The escalating prices of cancer medications have compelled several nations to seek cost-cutting measures.

Cancer drugs are highly specialized medicines with limited authorized indications, frequently specific to one or a combination of tumor sites, chemotherapy regimens, and treatment sequences. Typically, public payers limit reimbursement to certain specific conditions.

Patients with Medicare may or may not have to pay a portion of the cost of KEYTRUDA (pembrolizumab) based on their insurance plan. For example, with a Medicare Advantage plan, 41% of patients had no out-of-pocket costs for the 200 mg dose of KEYTRUDA. Roughly 80% of patients are responsible for a portion of the cost paid between USD 0 and USD 925 per infusion after meeting their deductible. Most patients with Medicaid typically pay USD 4–8 per KEYTRUDA infusion. The copay part, which needs to be paid by the patient, ranges from USD 12,045.

Further details related to reimbursement will be provided in the report….

triple-negative-breast-cancer-tnbc-market-outlook

Triple Negative Breast Cancer (TNBC) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Triple Negative Breast Cancer (TNBC) Market Size and Trends
  • Existing Market Opportunity

Triple Negative Breast Cancer (TNBC) Report Key Strengths

  • Ten-year Forecast
  • The 7MM Coverage
  • Triple Negative Breast Cancer (TNBC) Epidemiology Segmentation
  • Key Cross Competition

Triple Negative Breast Cancer (TNBC) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Market Attractiveness
  • Qualitative Analysis (SWOT)

Key Questions

  • Would there be any changes observed in the current treatment approach?
  • Will there be any improvements in Triple Negative Breast Cancer (TNBC) management recommendations?
  • Would technical advances pave the way for future therapies for Triple Negative Breast Cancer (TNBC)?
  • How would the emerging therapies fare against the already established approved treatment regimens?

1. Key Insights

2. Report Introduction

3. Triple Negative Breast Cancer (TNBC) Market Overview at a Glance

3.1. Market Share (%) Distribution of TNBC by Therapies in the 7MM in 2019

3.2. Market Share (%) Distribution of TNBC by Therapies in the 7MM in 2032

4. Executive Summary of TNBC

4.1. Key Events

5. Disease Background and Overview

5.1. Introduction

5.2. Various Subtypes of Breast Cancer Based on Immunohistochemical Expression

5.3. Triple Negative Breast Cancer (TNBC) Overview

5.3.1. Intrinsic Molecular Subtypes in TNBC

5.3.2. Characteristics of Tumor Microenvironment in TNBC

5.3.3. Potential Risk Factors

5.3.4. Clinical Presentation

5.3.5. Characterization of HER2-low Breast Cancers

5.4. Diagnosis

5.5. Staging

5.5.1. Details of the TNM Staging System

5.5.2. Grading

5.5.3. Clinical Prognostic Stage

5.5.4. Pathological Prognostic Stage

5.6. Diagnostic Algorithm

6. Treatment and Management

6.1. NCCN Clinical Practice Guidelines in Oncology for Breast Cancer

6.2. ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Early Breast Cancer

6.3. ESMO Clinical Practice Guideline for the Diagnosis, Staging, and Treatment of Patients With Metastatic Breast Cancer

6.4. Treatment Algorithm

7. Methodology

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. Assumptions and Rationale: 7MM

8.3. Total Incident Cases of Breast Cancer in the 7MM

8.4. Total Incident Cases of Triple Negative Breast Cancer (TNBC) in the 7MM

8.5. Epidemiology Scenario in the United States

8.5.1. Total Incident Cases of TNBC in the United States

8.5.2. Subtype-specific Cases of TNBC in the United States

8.5.3. Gene Mutation-specific Cases of TNBC in the United States

8.5.4. Stage-specific Cases of TNBC in the United States

8.5.5. Age-specific Cases of TNBC in the United States

8.5.6. Line wise Treated Cases of TNBC in the United States

8.6. Epidemiology Scenario in EU4 and the UK

8.6.1. Total Incident Cases of TNBC in EU4 and the UK

8.6.2. Subtype-specific Cases of TNBC in EU4 and the UK

8.6.3. Gene Mutation-specific Cases of TNBC in EU4 and the UK

8.6.4. Stage-specific Cases of TNBC in EU4 and the UK

8.6.5. Age-specific Cases of TNBC in EU4 and the UK

8.6.6. Line wise Treated cases of TNBC in EU4 and the UK

8.7. Epidemiology Scenario in Japan

8.7.1. Total Incident Cases of TNBC in Japan

8.7.2. Subtype-specific Cases of TNBC in Japan

8.7.3. Gene Mutation-specific Cases of TNBC in Japan

8.7.4. Stage-specific Cases of TNBC in Japan

8.7.5. Age-specific Cases of TNBC in Japan

8.7.6. Line wise Treated Cases of TNBC in Japan

9. Patient Journey

10. Marketed Products

10.1. Key-cross

10.2. LYNPARZA (olaparib): Astra Zeneca

10.2.1. Product Description

10.2.2. Regulatory Milestones

10.2.3. Clinical Developmental Activities

10.2.4. Safety and Efficacy

10.3. TALZENNA (talazoparib): Pfizer

10.3.1. Product Description

10.3.2. Regulatory Milestones

10.3.3. Clinical Developmental Activities

10.3.4. Safety and Efficacy

10.4. TECENTRIQ (atezolizumab): Hoffman-la Roche/Genentech Inc.

10.4.1. Product Description

10.4.2. Regulatory Milestones

10.4.3. Clinical Developmental Activities

10.4.4. Safety and Efficacy

10.5. TRODELVY (sacitzumab govitecan-hziy): Gilead Sciences

10.5.1. Product Description

10.5.2. Regulatory Milestones

10.5.3. Clinical Developmental Activities

10.5.4. Safety and Efficacy

10.6. KEYTRUDA (perbrolizumab): Merck Sharp & Dohme

10.6.1. Product Description

10.6.2. Regulatory Milestones

10.6.3. Clinical Developmental Activities

10.6.4. Safety and Efficacy

11. Emerging Therapies

11.1. Key-cross

11.2. COSELA (trilacicilib): G1 Therapeutics

11.2.1. Product Description

11.2.2. Other Developmental Activities

11.2.3. Clinical Developmental Activities

11.2.4. Safety and Efficacy

11.3. Datopotamab Deruxtecan (Dato-DXd): AstraZeneca/Daiichi Sankyo

11.3.1. Product Description

11.3.2. Other Developmental Activities

11.3.3. Clinical Developmental Activities

11.3.4. Safety and Efficacy

11.4. Capivasertib: AstraZeneca

11.4.1. Product Description

11.4.2. Other Developmental Activities

11.4.3. Clinical Developmental Activities

11.4.4. Safety and Efficacy

11.5. ZEN003694: Zenith Epigenetics/Pfizer

11.5.1. Product Description

11.5.2. Other Developmental Activities

11.5.3. Clinical Developmental Activities

11.5.4. Safety and Efficacy

11.6. TAVO (Tavokinogene Telseplasmid): OncoSec Medical Incorporated/Merck Sharp & Dohme LLC

11.6.1. Product Description

11.6.2. Other Developmental Activities

11.6.3. Clinical Developmental Activities

11.6.4. Safety and Efficacy

11.7. PVX-410: OncoPep

11.7.1. Product Description

11.7.2. Other Developmental Activities

11.7.3. Clinical Developmental Activities

11.7.4. Safety and Efficacy

11.8. IPI-549 (Eganelisib): Infinity Pharmaceuticals/Roche Pharma AG

11.8.1. Product Description

11.8.2. Other Developmental Activities

11.8.3. Clinical Developmental Activities

11.8.4. Safety and Efficacy

12. TNBC-Seven Major Market Analysis

12.1. Key Findings

12.2. Market Outlook

12.3. Conjoint Analysis

12.4. Key Market Forecast Assumptions

12.5. Seven Major Market Size

12.5.1. Total Market Size of TNBC in the 7MM

12.5.2. Market Size of TNBC by Therapies (First-line) in the 7MM

12.5.3. Market Size of TNBC by Therapies (Second-line) in the 7MM

12.5.4. Market Size of TNBC by Therapies (Third-line) in the 7MM

12.6. United States Market Size

12.6.1. Total Market Size of TNBC in the United States

12.6.2. Market Size of TNBC by Therapies (First-line) in the United States

12.6.3. Market Size of TNBC by Therapies (Second-line) in the United States

12.6.4. Market Size of TNBC by Therapies (Third-line) in the United States

12.7. EU4 and the UK Market Size

12.7.1. Total Market size of TNBC in EU4 and the UK

12.7.2. Market Size of TNBC by Therapies (First-line) in EU4 and the UK

12.7.3. Market Size of TNBC by Therapies (Second-line) in EU4 and the UK

12.7.4. Market Size of TNBC by Therapies (Third-line) in EU4 and the UK

12.8. Japan Market Size

12.8.1. Total Market size of TNBC in Japan

12.8.2. Market Size of TNBC by Therapies (First-line) in Japan

12.8.3. Market Size of TNBC by Therapies (Second-line) in Japan

12.8.4. Market Size of TNBC by Therapies (Third-line) in Japan

13. Market Access and Reimbursement

13.1. The United States

13.1.1. Centre for Medicare & Medicaid Services (CMS)

13.2. EU4 and the UK

13.2.1. Germany

13.2.2. France

13.2.3. Italy

13.2.4. Spain

13.2.5. United Kingdom

13.3. Japan

13.3.1. MHLW

14. KOL Views

15. Unmet Needs

16. SWOT Analysis

17. Appendix

17.1. Report Methodology

17.2. Bibliography

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

List of Tables:

    Table 1: Summary of TNBC Market, Epidemiology (2019–2032)

    Table 2: Key Events

    Table 3: Definitions for T, N, and M

    Table 4: Clinical Prognostic Staging

    Table 5: Pathological Prognostic Staging

    Table 6: Total Incident Cases of Breast Cancer in the 7MM (2019–2032)

    Table 7: Total Incident Cases of Triple Negative Breast Cancer (TNBC) in the 7MM (2019–2032)

    Table 8: Total Incident Cases of TNBC in the United States (2019–2032)

    Table 9: Subtype-specific Cases of TNBC in the United States (2019–2032)

    Table 10: Gene Mutation-specific Cases of TNBC in the United States (2019–2032)

    Table 11: Stage-specific Cases of TNBC in the United States (2019–2032)

    Table 12: Age-specific Cases of TNBC in the United States (2019–2032)

    Table 13: Line wise Treated Cases of TNBC in the US (2019–2032)

    Table 14: Total Incident Cases of TNBC in EU4 and the UK (2019–2032)

    Table 15: Subtype-specific Cases of TNBC in EU4 and the UK (2019–2032)

    Table 16: Gene Mutation-specific Cases of TNBC in EU4 and the UK (2019–2032)

    Table 17: Stage-specific Cases of TNBC in EU4 and the UK (2019–2032)

    Table 18: Age-specific cases of TNBC in EU4 and the UK (2019–2032)

    Table 19: Line wise Treated Cases of TNBC in EU4 and the UK (2019–2032)

    Table 20: Total Incident Cases of TNBC in Japan (2019–2032)

    Table 21: Subtype-specific Cases of TNBC in Japan (2019–2032)

    Table 22: Gene Mutation-specific Cases of TNBC in Japan (2019–2032)

    Table 23: Stage-specific Cases of TNBC in Japan (2019–2032)

    Table 24: Age-specific Cases of TNBC in Japan (2019–2032)

    Table 25: Line wise Treated Cases of TNBC in Japan (2019–2032)

    Table 27: Comparison of Marketed Drugs of TNBC

    Table 28: LYNPARZA, Clinical Trial Description, 2023

    Table 29: Early Breast Cancer Stage, Receptor Status, and Grade Scoring Requirements for Study Enrollment

    Table 30: Efficacy Results – OlympiA

    Table 31: Efficacy Results – OlympiAD (BICR-assessed)

    Table 32: TALZENNA, Clinical Trial Description, 2023

    Table 33: Summary of Efficacy Results – EMBRACA Study

    Table 34: TECENTRIQ, Clinical Trial Description, 2023

    Table 35: Efficacy Results from IMpassion130 in Patients with PD-L1 Expression = 1%

    Table 36: TRODELVY, Clinical Trial Description, 2023

    Table 37: Efficacy Results From ASCENT

    Table 38: Efficacy results for patients with mTNBC in IMMU-132-01

    Table 39: KEYTRUDA, Clinical Trial Description, 2023

    Table 40: Efficacy Results – KEYNOTE-522

    Table 41: Efficacy Results in KEYNOTE-355 (CPS =10)

    Table 42: Comparison of Emerging drugs of TNBC

    Table 43: COSELA (trilacicilib), Clinical Trial Description, 2023

    Table 44: Datopotamab Deruxtecan (Dato-DXd), Clinical Trial Description, 2023

    Table 45: Capivasertib, Clinical Trial Description, 2023

    Table 46: ZEN003694, Clinical Trial Description, 2023

    Table 47: TAVO, Clinical Trial Description, 2023

    Table 48: PVX-410, Clinical Trial Description, 2023

    Table 49: IPI-549, Clinical Trial Description, 2023

    Table 50: Key Market Forecast Assumptions for COSELA + gemcitabine + carboplatin

    Table 51: Key Market Forecast Assumptions for COSELA + TRODELVY

    Table 52: Key Market Forecast Assumptions for Datopotamab deruxtecan (Dato-DXd)

    Table 53: Key Market Forecast Assumptions for Capivasertib

    Table 54: Key Market Forecast Assumptions for ZEN003694

    Table 55: Key Market Forecast Assumptions for TAVO

    Table 56: Key Market Forecast Assumptions for IPI-549 (eganelisib)

    Table 57: Key Market Forecast Assumptions for TRODELVY (sactizumab govtecan-hziy)

    Table 58: Key Market Forecast Assumptions for KEYTRUDA (pembrolizumab)

    Table 59: Total Market Size of TNBC in the 7MM, in USD million (2019–2032)

    Table 60: Market Size of TNBC by Therapies (First-line) in the 7MM, in USD million (2019–2032)

    Table 61: Market Size of TNBC by Therapies (Second-line) in the 7MM, in USD million (2019–2032)

    Table 62: Market Size of TNBC by Therapies (Third-line) in the 7MM, in USD million (2019–2032)

    Table 63: Total Market Size of TNBC in the United States, in USD million (2019–2032)

    Table 64: Market Size of TNBC by Therapies (First-line) in the United States, in USD million (2019–2032)

    Table 65: Market Size of TNBC by Therapies (Second-line) in the United States, in USD million (2019–2032)

    Table 66: Market Size of TNBC by Therapies (Third-line) in the United States, in USD million (2019–2032)

    Table 67: Total Market Size of TNBC in EU4 and the UK, in USD million (2019–2032)

    Table 68: Market Size of TNBC by Therapies (First-line) in EU4 and the UK, in USD million (2019–2032)

    Table 69: Market Size of TNBC by Therapies (Second-line) in EU4 and the UK, in USD million (2019–2032)

    Table 70: Market Size of TNBC by Therapies (Third-line) in EU4 and the UK, in USD million (2019–2032)

    Table 71: Total Market Size of TNBC in Japan, in USD million (2019–2032)

    Table 72: Market Size of TNBC by Therapies (First-line) in Japan, in USD million (2019–2032)

    Table 73: Market Size of TNBC by Therapies (Second-line) in Japan, in USD million (2019–2032)

  • Table 74: Market Size of TNBC by Therapies (Third-line) in Japan, in USD million (2019–2032)

List of Figures:

    Figure 1: Intrinsic Molecular Subtypes of Breast Cancer

    Figure 2: Classification of Neoplastic Infiltrating Lymphocytes

    Figure 3: Type of Tumor-associated Macrophages

    Figure 4: Diagnostic Work-up and Staging of Metastatic Breast Cancer

    Figure 5: Line-wise Treatment Recommendations of NCCN for TNBC

    Figure 6: Treatment Algorithm of Metastatic TNBC

    Figure 7: Total Incident Cases of Breast Cancer in the 7MM (2019–2032)

    Figure 8: Total Incident Cases of Triple Negative Breast Cancer (TNBC) in the 7MM (2019–2032)

    Figure 9: Total Incident Cases of TNBC in the United States (2019–2032)

    Figure 10: Subtype-specific Cases of TNBC in the United States (2019–2032)

    Figure 11: Gene Mutation-specific Cases of TNBC in the United States (2019–2032)

    Figure 12: Stage-specific Cases of TNBC in the United States (2019–2032)

    Figure 13: Age-specific Cases of TNBC in the United States (2019–2032)

    Figure 14: Line wise Treated Cases of TNBC in the US (2019–2032)

    Figure 15: Total Incident Cases of TNBC in EU4 and the UK (2019–2032)

    Figure 16: Subtype-specific Cases of TNBC in EU4 and the UK (2019–2032)

    Figure 17: Gene Mutation-specific Cases of TNBC in EU4 and the UK (2019–2032)

    Figure 18: Stage-specific Cases of TNBC in EU4 and the UK (2019–2032)

    Figure 19: Age-specific Cases of TNBC in EU4 and the UK (2019–2032)

    Figure 20: Line wise Treated Cases of TNBC in EU4 and the UK (2019–2032)

    Figure 21: Total Incident Cases of TNBC in Japan (2019–2032)

    Figure 22: Subtype-specific Cases of TNBC in Japan (2019–2032)

    Figure 23: Gene Mutation-specific Cases of TNBC in Japan (2019–2032)

    Figure 24: Stage-specific Cases of TNBC in Japan (2019–2032)

    Figure 25: Age-specific Cases of TNBC in Japan (2019–2032)

    Figure 26: Line wise Treated cases of TNBC in Japan (2019–2032)

    Figure 27: Market Size of TNBC by Therapies (First-line) in the 7MM, in USD million (2019–2032)

    Figure 28: Market Size of TNBC by Therapies (Second-line) in the 7MM, in USD million (2019–2032)

    Figure 29: Market Size of TNBC by Therapies (Third-line) in the 7MM, in USD million (2019–2032)

    Figure 30: Total Market Size of TNBC in the United States, in USD million (2019–2032)

    Figure 31: Market Size of TNBC by Therapies (First-line) in the United States, in USD million (2019–2032)

    Figure 32: Market Size of TNBC by Therapies (Second-line) in the United States, in USD million (2019–2032)

    Figure 33: Market Size of TNBC by Therapies (Third-line) in the United States, in USD million (2019–2032)

    Figure 34: Total Market Size of TNBC in EU4 and the UK, in USD million (2019–2032)

    Figure 35: Market Size of TNBC by Therapies (First-line) in EU4 and the UK, in USD million (2019–2032)

    Figure 36: Market Size of TNBC by Therapies (Second-line) in EU4 and the UK, in USD million (2019–2032)

    Figure 37: Market Size of TNBC by Therapies (Third-line) in EU4 and the UK, in USD million (2019–2032)

    Figure 38: Total Market Size of TNBC in Japan, in USD million (2019–2032)

    Figure 39: Market Size of TNBC by Therapies (First-line) in Japan, in USD million (2019–2032)

    Figure 40: Market Size of TNBC by Therapies (Second-line) in Japan, in USD million (2019–2032)

    Figure 41: Market Size of TNBC by Therapies (Third-line) in Japan, in USD million (2019–2032)

    Figure 42: Health Technology Assessment

    Figure 43: Reimbursement Process in Germany

    Figure 44: Reimbursement Process in France

    Figure 45: Reimbursement Process in Italy

    Figure 46: Reimbursement Process in Spain

    Figure 47: Reimbursement Process in the United Kingdom

    Figure 48: Reimbursement Process in Japan

  • Figure 49: Unmet Needs

List of Companies:

  • G1 Therapeutics
  • AstraZeneca
  • Daiichi Sankyo
  • Zenith Epigenetics
  • Pfizer
  • OncoSec Medical Incorporated
  • Merck Sharp & Dohme LLC
  • Infinity Pharmaceuticals
  • Roche Pharma AG
  • OncoPep

Frequently Asked Questions

Triple Negative Breast Cancer (TNBC) is defined as a tumor where the estrogen and progesterone (ER/PR) are negative, as assessed by immunohistochemistry (IHC), and there is a lack of overexpression of HER2, as assessed by immunohistochemistry (IHC), or the absence of its gene amplification, as assessed by fluorescence in situ hybridization technique.

Triple Negative Breast Cancer epidemiology is segmented as Total Incident Cases of Triple Negative Breast Cancer, Age-specific cases of Triple Negative Breast Cancer, Gender-specific Cases of Triple Negative Breast Cancer, Stage-specific incident cases of Triple Negative Breast Cancer, Type-specific incident cases of Triple Negative Breast Cancer, and Total Treated Cases of Triple Negative Breast Cancer.

Some of the Triple Negative Breast Cancer therapies are KEYTRUDA (pembrolizumab), TRODELVY (sacituzumab govitecan-hziy), IPI-549 (Eganelisib), Imprime PGG, Paclitaxel (Abraxane), Erbulin (Halaven), Carboplatin, Cisplatin, Docetaxel and others

Some of the Triple Negative Breast Cancer companies working in the market are AstraZeneca, Gilead Science, Infinity Pharmaceuticals, HiberCell, Hoffmann-La Roche, Immunomedics, Merck, HiberCell, Infinity Pharmaceuticals, CytoDyn, and Many Others.

Key strengths of the Triple Negative Breast Cancer Market Report are 11 Years Forecast, 7MM Coverage, Epidemiology Segmentation, Market Size, Drug Uptake, Pipeline Therapies, Market Drivers, and Market Barriers, along with the upcoming market trends in the Triple Negative Breast Cancer Market.

The United States is expected to account for the highest prevalent Triple Negative Breast Cancer cases.

Related Reports

Triple Negative Breast Cancer (TNBC) - Market Insight, Epidemiology and Market Forecast - 2027

Triple Negative Breast Cancer (TNBC) - Market Insight, Epidemiology and Market Forecast - 2027

Triple Negative Breast Cancer (TNBC) - Market Insight, Epidemiology and Market Forecast - 2028

Triple Negative Breast Cancer (TNBC) - Market Insight, Epidemiology and Market Forecast - 2028

Tags:

loader

Request Sample

View Pricing